Foghorn Therapeutics (NASDAQ:FHTX) remains a "hold" rating based on the fact that it is in the process of developing its lead candidate FHD-909 for the treatment of solid tumor patients who ...
INDIANAPOLIS, March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be ...
You’re an individual who is truly unique. We celebrate the passions that drive you and the possibilities that inspire you. Here, a degree is a pursuit of purpose where learning empowers you, ...
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on ...
INDIANAPOLIS, March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback